Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression

Acquired drug resistance is a major factor limiting the effectiveness of targeted cancer therapies. Targeting tumors with kinase inhibitors induces complex adaptive programs that promote the persistence of a fraction of the original cell population, facilitating the eventual outgrowth of inhibitor-r...

Full description

Saved in:
Bibliographic Details
Published in:Cancer discovery 2018-01, Vol.8 (1), p.59-73
Main Authors: Rusan, Maria, Li, Kapsok, Li, Yvonne, Christensen, Camilla L, Abraham, Brian J, Kwiatkowski, Nicholas, Buczkowski, Kevin A, Bockorny, Bruno, Chen, Ting, Li, Shuai, Rhee, Kevin, Zhang, Haikuo, Chen, Wankun, Terai, Hideki, Tavares, Tiffany, Leggett, Alan L, Li, Tianxia, Wang, Yichen, Zhang, Tinghu, Kim, Tae-Jung, Hong, Sook-Hee, Poudel-Neupane, Neermala, Silkes, Michael, Mudianto, Tenny, Tan, Li, Shimamura, Takeshi, Meyerson, Matthew, Bass, Adam J, Watanabe, Hideo, Gray, Nathanael S, Young, Richard A, Wong, Kwok-Kin, Hammerman, Peter S
Format: Article
Language:English
Subjects:
Cell Line, Tumor
Humans
Neoplasms - pathology
Neoplasms - therapy
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acquired drug resistance is a major factor limiting the effectiveness of targeted cancer therapies. Targeting tumors with kinase inhibitors induces complex adaptive programs that promote the persistence of a fraction of the original cell population, facilitating the eventual outgrowth of inhibitor-resistant tumor clones. We show that the addition of a newly identified CDK7/12 inhibitor, THZ1, to targeted therapy enhances cell killing and impedes the emergence of drug-resistant cell populations in diverse cellular and cancer models. We propose that targeted therapy induces a state of transcriptional dependency in a subpopulation of cells poised to become drug tolerant, which THZ1 can exploit by blocking dynamic transcriptional responses, promoting remodeling of enhancers and key signaling outputs required for tumor cell survival in the setting of targeted therapy. These findings suggest that the addition of THZ1 to targeted therapies is a promising broad-based strategy to hinder the emergence of drug-resistant cancer cell populations. CDK7/12 inhibition prevents active enhancer formation at genes, promoting resistance emergence in response to targeted therapy, and impedes the engagement of transcriptional programs required for tumor cell survival. CDK7/12 inhibition in combination with targeted cancer therapies may serve as a therapeutic paradigm for enhancing the effectiveness of targeted therapies. .
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.cd-17-0461